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a b s t r a c t
As a member of peroxiredoxin (Prx) family, PrxIII is predominantly located in mitochondria and plays
an important role as a scavenger of reactive oxygen species (ROS). Since previous reports demonstrated
over-expression of PrxIII in cervical cancer, we conducted the present study to investigate the signiﬁ-
cance of PrxIII in cervical cancer development and/or progression.
Cervical cancer cells were cultured from tissues derived from cervical cancer patients. After successful
knockdown of PrxIII expression by small interfering RNA, we evaluated ROS level, viable cell number,
and apoptosis of cervical cancer cells along with the culture time.
The production of ROS was increased in cervical cancer cells as compared with normal cervical ep-
ithelia. Knockdown of PrxIII expression induced up-regulation of other Prx members including PrxI,
PrxII, and PrxV. ROS level was higher in down-regulated cervical cancer cells than in controls and the
differencewas increasingwith culture time.We also observed increased apoptosis and decreased viable
cell number in down-regulated cervical cancer cells.
Our results suggest that PrxIII is an indispensable ROS scavenger, which protects tumor cells against
oxidative damage and subsequent apoptosis.
C© 2013 The Authors. Published by Elsevier B.V. on behalf of Federation of European Biochemical
Societies.
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As an energy-provider for cellular activities, mitochondrion is a
major source of reactive oxygen species (ROS) production. Since ex
cessive ROSmay cause oxidative damage onDNA, lipids, and proteins
organisms have developed multiple antioxidant systems to contro
the ROS at baseline level that serves as cellular second messengers
Under pathophysiological conditions or outer stimuli, ROS generation
is exaggerated to an extent that overwhelms cellular antioxidant de
fenses and a state called “oxidative stress” occurs. As a member o
peroxiredoxin (Prx) family, PrxIII is mainly located in mitochondria
By reducing H2O2 with its two active cysteines, PrxIII acts as a mi
tochondrial scavenger of ROS, which protects mitochondria agains
oxidative damage and inﬂuences diverse cellular processes including
growth, differentiation, apoptosis, and carcinogenesis [1–3].
Up to now, accumulating evidence demonstrated that PrxIII wa
up-regulated in various types of carcinomas [4–7]. According to the* Corresponding authors. Address: Obstetrics and Gynecology Center, Tsinghua
University Second Hospital, 5 Shijingshan Road, Shijingshan-District, Beijing 100049,
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http://dx.doi.org/10.1016/j.fob.2012.12.002report by Kim et al., PrxIII expression was increased with the severity
of cervical lesions [8].We recently demonstrated that PrxIII was over-
expressed in cervical cancer and the immunostaining pattern was
consistentwith thatof theproliferationmarkerKi67 [9], suggestingan
active response of PrxIII to cell expansion-induced oxidative stress in
cervical cancer. Nevertheless, the precise function of PrxIII in cervical
cancer development and/or progression remains to be obscure. The
present study was conducted to investigate the signiﬁcance of PrxIII
in cervical cancer cells.
2. Material and methods
This study was approved by the Institutional Review Boards of
Tsinghua University Medical School. All samples were obtained af-
ter informed consent from patients at Tsinghua University Second
Hospital. Cervical cancer tissues from squamo-columnar zone were
obtained from 10 patients who underwent radical surgery. The mean
age of the cancer patients was 50.2 ± 2.6. All the patients were diag-
nosed as squamous cervical cancer stage IA according to the Interna-
tional Federation of Gynaecology and Obstetrics criteria for cervical
carcinoma.
2.1. Cell culture
Cancerous tissues and the adjacent normal epithelial tissues were
cut and cultured separately at the same time. Primary culture wasropean Biochemical Societies.Open access under CC BY-NC-ND license.
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Table 1
Primer sequences for qRT-PCR analysis.
Genes Sequences
Size
(bp)
PrxI Forward 5′-TATGCCAGATGGTCAGTTT-3′
Reverse 5′-CCCAGTCCTCCTTGTTTC-3′ 166
PrxII Forward 5′-TGTCGGACTACAAAGGGAA-3′
Reverse 5′-GACGCCCAGCACTTCACA-3′ 203
PrxIII Forward 5′-TGCCTGGATAAATACACC-3′
Reverse 5′-AGTCTCGGGAAATCTGCT-3′ 198
PrxIV Forward 5′-GCTGGGAGACAGAGGAGA-3′
Reverse 5′-AAATGTGAAATCAAGTGGG-3′ 156
PrxV Forward 5′-ATTCGCTGGTGTCCATCTTT-3′
Reverse 5′-GTGCCATCTGGTTCCACATTCA-3′ 211
PrxVI Forward 5′-ATTCTCAGGGTAGTCATCTC-3′
Reverse 5′-TTTGGCTTCTTCTTCAGG-3′ 179
β-actin Forward 5′-ACGTTGACATCCGAAAGACC-3′
Reverse 5′- CCACCGATCCACACAGAGTA-3′ 154
performed in keratinocyte serum-free medium (Invitrogen Corpora-
tion) supplemented with human recombinant EGF, bovine pituitary
extract, and antibiotics. All cells weremaintained at 37 ◦C in a humid-
iﬁed incubator with 5% CO2 and passaged at a 1:4 split ratio.
2.2. Knockdown of PrxIII expression
Cells at passage 3were seeded in six-well plateswith a density of 1
× l06 cells/ml.After culture for24h, down-regulationof PrxIII expres-
sion was achieved by small interfering RNA (siRNA) that targeted the
5′-GCCAAGUCCAGCUGCUUCCTT-3′ sequence of human PrxIII mRNA.
The interfering effectiveness was conﬁrmed by Western blot analy-
sis using mouse monoclonal antibody against human PrxIII (1:1000
dilution, Abcam Biochemicals).
2.3. Changes of PrxIII and other Prx genes
Expression changes of PrxIII and other Prx genes in PrxIII-
knockdown cells were analyzed by Western blot and quantitative
real-time PCR (qRT-PCR) as described previously [10]. The primer se-
quences for qRT-PCR were summarized in Table 1. We used mouse
monoclonal anti-2 Cys Prx antibody to recognize 2-cys Prxs (1:1000
dilution, Abcam Biochemicals).
2.4. Detection of ROS level
Detection of ROS levelwasperformedas previously described [11].
Brieﬂy, harvested cells at passage 3 were re-cultured overnight in
six-well plates (1 × 106 cells/ml) with 4 ml of serum- and phenol
red-free medium per well. After incubation for 20 min with 2 μM
2′,7′-dichloroﬂuorescin diacetate (DCFH-DA, Molecular Probes), the
ROS levels in cancer cells and the adjacent normal epithelia were
respectively estimated at indicated time points through the oxidation
of DCFH-DA. After siRNA experiment, we detected ROS level in six
PrxIII-knockdown cancer cell lines and six control cancer cell lines
respectively.
2.5. Evaluation of cell apoptosis and viable cell number
After conﬁrmation of PrxIII down-regulation, cancer cells were
harvested and sub-cultured in 96-well plates at a density of 1 × l04
cells/ml for 48 h. Cell apoptosiswas detected by ﬂow cytometry using
Annexin V-FITC Kit (Invitrogen). In addition, we used Cell Counting
Kit-8 (CCK8, Dojindo Laboratories, Japan) to evaluate the number of
viable cells. This assaywas based on the conversion of tetrazolium salt
WST-8 to formazan. The amount of yellow-colored formazan gener-
ated by the activity of mitochondrial dehydrogenases in cells was
Fig. 1. Expression of PrxIII and other 2-Cys Prx genes in cervical cancer cells analyzed
by Western blot. (A) The PrxIII expression was signiﬁcantly inhibited by siRNA. There
was no signiﬁcant difference of PrxIII expression among cells without transfection
(Con), cells transfected with siRNA containing the 5′-UUCUCCGAACGUGUCACGUTT-
3′ sequence (SiNc), and cells transfected with Lipo-fectamine only (SiLipo). (B) The
expression of other 2-Cys Prx genes was up-regulated after knockdown of PrxIII.
Fig. 2. Expression analysis of Prx genes by qRT-PCR. After knockdown of PrxIII expres-
sion (SiPrxIII vs. SiNc: **P < 0.01), other Prx genes including PrxI, PrxII, and PrxV were
signiﬁcantly up-regulated (SiPrxIII vs. SiNc: *P < 0.05).
directly proportional to the number of living cells. OD450nm was
assayed at indicated time points.
2.6. Statistical analysis
Data was presented as mean± SD of three separate experiments.
Cell apoptosis, viable cell number, andROS level betweenPrxIII down-
regulated cells and controls were compared by analysis of variance.
It was considered a signiﬁcant difference when P < 0.05.
3. Results
3.1. Knockdown of PrxIII expression induced up-regulation of other Prx
genes
Among the 10 patientswith stage IA cervical cancer, six caseswere
successfully cultured for both cancerous cells and adjacent normal ep-
ithelia. We used these cells (tentatively called “cell lines”) to perform
siRNA experiment. As shown in Fig. 1(A), PrxIII expression in can-
cer cells was signiﬁcantly down-regulated after siRNA. Interestingly,
other Prx members were signiﬁcantly up-regulated after knockdown
of PrxIII expression (Fig. 1(B)). qRT-PCR analysis recognized that the
up-regulated Prx members included PrxI, PrxII, and PrxV (Fig. 2). We
achieved the similar effectiveness of PrxIII down-regulation and ob-
served the similar compensation of other Prx members in adjacent
normal epithelia (data not shown).
3.2. ROS level was increased in PrxIII down-regulated cancer cells
We compared the ROS level in the six cancer cell lines to that in
the six epithelial cell lines. As shown in Fig. 3(A), the ROS production
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Fig. 3. Detection of ROS level in cervical cells by DCF ﬂuorescence. (A) The ROS produc-
tion in cervical cancer cells (Ca) was higher than that in the adjacent normal epithelia
(Adj) and the difference was increasing with culture time (Ca vs. Adj: **P < 0.01 from
24 h point). (B) After down-regulation of PrxIII in cervical cancer cells, the ROS level
was increased and reached a signiﬁcant difference from 24 h point as compared with
controls (SiPrxIII vs. SiNc: *P < 0.05 at 24 h point, **P < 0.01 at 48 h and 72 h points
respectively).
was higher in cervical cancer cells than in adjacent normal epithe-
lia and the difference was increasing with culture time (Ca vs. Adj:
P < 0.01 from 24 h point). To examine the signiﬁcance of PrxIII in
removing ROS, we compared the ROS level in cancerous cells before
and after knockdown of PrxIII. As indicated in Fig. 3(B), the ROS level
was signiﬁcantly increased in PrxIII down-regulated cancer cells as
compared with control cancer cells (SiPrxIII vs. SiNc: P < 0.05 at 24
h-point; P < 0.01 at 48 h and 72 h-points respectively).
3.3. Cell apoptosis was enhanced after knockdown of PrxIII expression
To investigate the signiﬁcance of PrxIII in apoptotic regulation, we
compared the apoptotic percentage in six cancer cell lineswith PrxIII-
knockdown to that in six cancer cell lines without PrxIII-knockdown.
After transfection of SiPrxIII, the apoptotic percentage was signiﬁ-
cantly higher (5.64 ± 1.76%) as compared with controls (0.67 ±
0.53%) (SiPrxIII vs. SiNc: P< 0.01). At the same time, we observed sig-
niﬁcant decrease of viable cell number after PrxIII down-regulation
(Fig. 4, SiPrxIII vs. SiNc: P < 0.05).
4. Discussion
In the present study, we provided direct evidence that the ROS
production was increased in cervical cancer cells as compared with
normal epithelia. After down-regulation of PrxIII expression, we no-
ticed further increase of the ROS level and subsequent apoptosis in
cancer cells, although other Prx members provided compensation to
some extents. Our results suggest that PrxIII is an indispensable ROS
scavenger in cervical cancer cells.
Because of active and indeﬁnite growth of cancer cells, ROS pro-
duction from mitochondria is accordingly increased [12]. It has been
reported that excessive ROSmay result in disruption ofmitochondrial
Fig. 4. The number of viable cervical cancer cells along with culture time analyzed by
Cell Counting Kit-8 (CCK8).We detected signiﬁcant decrease of viable cell number after
PrxIII down-regulation (SiPrxIII vs. SiNc: *P< 0.05 at 48 h and 72 h points respectively).
membrane permeabilization and alteration of mitochondrial mem-
brane transition pores, which leads to the release of apoptotic effec-
tors [13–15]. Since mitochondrion is the main apoptotic mediator,
it is imaginable that the control of ROS level by PrxIII is involved
in apoptotic inhibition. In fact, accumulating studies have suggested
that PrxIII plays an active inhibitory role in chemical-induced oxi-
dation and subsequent apoptosis [16–18]. According to the report by
Coxet al., PrxIII provided theﬁrst-line response to oxidative stress and
acted as a “trigger” in the apoptosis-signaling pathway of cancerous
cells [19].
By using cervical cancer cell lines, Shih et al. and Chang et al.
demonstrated that PrxIIIwas responsive to oxidation-inducing chem-
icals and protected against oxidative apoptosis [20,21]. To the best of
our knowledge, there have been few reports concerning the role of
PrxIII in cervical cancer cells at “natural state”. In the present study,
we successfully cultured primary cervical cancer cells and showed
that PrxIII silence in cervical cancer cells resulted in increased apop-
tosis and decreased proliferation. Our results suggest that PrxIII plays
an important role in apoptotic inhibition of cervical cancer cells by
controlling ROS level. This study can explain at least partially the
underlying mechanism for the over-expression of PrxIII in diverse
type carcinomas including cervical cancer. Fast growing cancer cells
produce large amount of ROS that disturb the redox balance. As an
active responder to oxidative stress, PrxIII is accordingly up-regulated
to remove cellular ROS and inhibit apoptosis, which is beneﬁcial to
cancerous growth and invasion. Sincemost of chemotherapy or radio-
therapy for cancers is through ROS increase and apoptotic induction,
our results have provided a clue that PrxIII may be involved in the
chemotherapeutic resistance of cervical cancer.
We previously reported that PrxI provided a compensatory func-
tion in the absence of PrxIII inmouse erythrocytes [10]. In the present
study, we showed that PrxIII silence in cervical cancer cells resulted
in the up-regulation of PrxI, PrxII, and PrxV. Our result implies that
the members of Prx family respond cooperatively to oxidative stress
in cervical cancer cells.
5. Conclusion
Combining the present study with previous reports of PrxIII over-
expression in cervical cancer [8,9], we conclude that PrxIII is an im-
portant regulator of intracellular ROS, which provides a favorable
microenvironment for tumor growth and protects against oxidation-
induced apoptosis. Our results have provided a new clue to the un-
derstanding of the mechanism for tumor progression or recurrence.
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